MEDXF News and Press, Medexus Pharmaceuticals Inc From 02/10/22

Medexus Pharmaceuticals, Inc (MEDXF) Q3 2022 Earnings Conference Call February 10, 2022, 08:00 AM ET Company Participants Ken d’Entremont – Chief Executive Officer Marcel Konrad – Chief Financial Officer Victoria Rutherford – Investor Relations Conference Call Part...

Achieved $21.3 million revenue driven by a recovery in IXINITY sales Treosulfan NDA resubmission expected in second calendar quarter 2022 with final FDA decision anticipated 2-6 months after resubmission Available liquidity of $10.1 million at end of period Management to host ...

TORONTO and CHICAGO, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that it will be presenting at The MicroCap Rodeo’s 2 nd Annual Winter Wonderland Best...

TORONTO and CHICAGO, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSX: MDP) (OTCQX: MEDXF) today announced that it plans to host a conference call at 8:00 AM Eastern Time on Thursday, February 10 th , 2022, to d...

RALEIGH, NC / ACCESSWIRE / January 28, 2022 / The Winter Wonderland Best Ideas Virtual Investor Conference will take place on February 8 th - 11 th , 2022, where 36 SmallCap, MicroCap and NanoCap public companies will be presenting via virtual webcast to a global investor audience. The vir...

TORONTO and CHICAGO, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “ Company ” or “Medexus ”) (TSX: MDP) (OTCQX: MEDXF) today announced that Ken d’Entremont, Chief Executive Officer of Medexus, and Marcel Konrad, Chief Financi...

LOS ANGELES, CA / ACCESSWIRE / December 6, 2021 / The SNN Network Canada Virtual Event will take place on December 7-9, 2021, where 70 SmallCap, MicroCap and NanoCap public and private companies will be presenting via virtual webcast to a global investor audience. The SNN Network Canada Vir...

TORONTO and CHICAGO, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “ Company ” or “Medexus ”) (TSX: MDP) (OTCQX: MEDXF) today announced that Ken d’Entremont, Chief Executive Officer of Medexus, and Marcel Konrad, Chief Financi...

NDA resubmission expected in second calendar quarter 2022 (previously anticipated timeline) Final FDA decision expected 2 to 6 months after NDA resubmission No additional Phase III study is required TORONTO and CHICAGO, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Me...

Small and Micro-cap investors are invited to attend the Q4 Investor Summit being held on November 16-17, 2021. The event is organized by the Investor Summit Group, recognised as a highly reputed brand for hosting North America’s largest independent investor conferences. Over 90 pre...